Search research articles
Contact Us
Filters
Showing results (211-220 of 248) with videos related to
Page
of 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
British Journal of Cancer
|
July 12, 2019
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients
Dae-Won Lee, Han Suk Ryu, Min-Sun Jin, et al.
British Journal of Cancer
|
June 17, 2016
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
Yongjun Cha, Kyung-Ju Kim, Sae-Won Han, et al.
British Journal of Cancer
|
November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
JAMA Oncology
|
July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Annals of Surgical Oncology
|
June 4, 2014
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX
Dae-Won Lee, Kyung Ju Kim, Sae-Won Han, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Changhee Park, Koung Jin Suh, Se Hyun Kim, et al.
Lancet (London, England)
|
November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Page
of 25
Search research articles
Search
Showing results (211-220 of 248) with videos related to
Sort By:
Page
of 25
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
British Journal of Cancer
|
July 12, 2019
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients
Dae-Won Lee, Han Suk Ryu, Min-Sun Jin, et al.
British Journal of Cancer
|
June 17, 2016
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
Yongjun Cha, Kyung-Ju Kim, Sae-Won Han, et al.
British Journal of Cancer
|
November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
JAMA Oncology
|
July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Ji-Yeon Kim, Seock-Ah Im, Kyung Hae Jung, et al.
Annals of Surgical Oncology
|
June 4, 2014
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX
Dae-Won Lee, Kyung Ju Kim, Sae-Won Han, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Changhee Park, Koung Jin Suh, Se Hyun Kim, et al.
Lancet (London, England)
|
November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Page
of 25